psalexa
logo

Aneurysmal Subarachnoid Hemorrhage Therapeutics Pipeline Analysis

Aneurysmal Subarachnoid Hemorrhage Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Delivery : 1-2 Working Days
Report Code: LS11217
Available Format:

Aneurysmal subarachnoid hemorrhage is a disorder that is characterized by loss of consciousness, sudden severe headache, epileptic seizures, and neurological symptoms such as hemisensory or motor symptoms and dysphagia. The disease can be diagnosed by blood count test, urea and electrolytes test, serum glucose test, chest radiography, lumbar puncture, and computed tomography. The complications associated with aneurysmal subarachnoid haemorrhage include hydrocephalus, seizures, hyponatremia, immediate cerebral ischemia, and cardiopulmonary dysfunction. It has been observed that one in four people having sudden severe headache is found to be suspected with aneurysmal subarachnoid hemorrhage. The Göteborg University is in the process of developing OSU 6162 as a dopamine D2 receptor modulator for the treatment of aneurysmal subarachnoid hemorrhage. The Radboud University is in the process of developing deferoxamine as an iron chelating agent for the treatment of aneurysmal subarachnoid hemorrhage. Some of the universities and companies having the pipeline of aneurysmal subarachnoid hemorrhage include Thomas Jefferson University, Edge Therapeutics, Inc., and others.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 3250
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 4000
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry